PARP

By Targets:	PARP (177) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (2) Antibiotic (1) Apoptosis (82) Aryl Hydrocarbon Receptor (1) Autophagy (13) Bacterial (2) Bcl-2 Family (11) c-Met/HGFR (1) c-Myc (1) Caspase (19) CDK (6) CFTR (1) Checkpoint Kinase (Chk) (1) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (2) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) Dynamin (1) E3 Ligase Ligand-Linker Conjugates (4) EGFR (2) Endogenous Metabolite (9) Epigenetic Reader Domain (4) Eukaryotic Initiation Factor (eIF) (1) FGFR (2) HDAC (7) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (1) Histone Methyltransferase (2) HIV (1) IAP (1) IGF-1R (1) Influenza Virus (1) IRAK (1) Isotope-Labeled Compounds (2) JNK (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (1) Microtubule/Tubulin (6) Mitophagy (4) Molecular Glues (2) Nucleoside Antimetabolite/Analog (7) P-glycoprotein (3) p38 MAPK (5) Parasite (5) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (2) Poly(ADP-ribose) Glycohydrolase (PARG) (2) PPAR (3) PROTAC Linkers (2) PROTACs (7) Proteasome (1) Reactive Oxygen Species (2) Reverse Transcriptase (1) ROS Kinase (1) Sirtuin (5) Small Interfering RNA (siRNA) (25) STAT (2) Survivin (1) Target Protein Ligand-Linker Conjugates (1) Topoisomerase (2) VEGFR (2)
By Research Areas:	Cancer (216) Cardiovascular Disease (7) Infection (7) Inflammation/Immunology (16) Metabolic Disease (7) Neurological Disease (20)
Click Chemistry:	PROTAC Synthesis (1) Azide (3) Alkynes (2)

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125218

PARP11 inhibitor ITK7 ITK7	PARP	Cancer
PARP11 inhibitor ITK7 (ITK7) is a potent and selective *PARP11* inhibitor. PARP11 inhibitor ITK7 can potently inhibit PARP11 with an IC₅₀ value of 14 nM. PARP11 inhibitor ITK7 can be used for the research of cellular localization . PARP11 inhibitor ITK7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a *PARP-1* inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma .

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent *PARP-1* inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of *PARP* and HDAC. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and HDAC1 with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a *PARP-1* inhibitor (IC₅₀ = 19.24 nM for *PARP-1* and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-148754

PARP10-IN-3	PARP	Cancer
PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 1.7 μM for human PARP2 and human PARP15, respectively .

HY-D1188

PARP7-probe-1	PARP	Cancer
PARP7-probe-1 is a chemiluminescent labeled *PARP7* probe. PARP7-probe-1 is a biotinylated probe binding to the PARP7 active site. PARP7-probe-1 can be used for the research of PARP7 function .

HY-148753

PARP10-IN-2	PARP	Cancer
PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively .

HY-151625

PARP-2-IN-3	PARP Apoptosis	Cancer
PARP-2-IN-3 (Compound 12) is a potent *PARP-2* inhibitor with an IC₅₀ of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability .

HY-102035

PARP-2-IN-1

PARP Cancer

PARP-2-IN-1 is a potent and selective PARP-2 inhibitor with an IC₅₀ of 11.5 nM.

PARP-2-IN-1	PARP	Cancer
PARP-2-IN-1 is a potent and selective *PARP-2* inhibitor with an IC₅₀ of 11.5 nM.

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer .

HY-132297

PARP1-IN-5

PARP Cancer

PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-151624

PARP-2-IN-2	PARP Apoptosis	Cancer
PARP-2-IN-2 (compound 27) is a *PARP‑2* inhibitor with an IC₅₀ value of 0.057 µM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a *PARP1* inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-155122

PARP-1-IN-13	PARP	Cancer
PARP-1-IN-13 (Compound 19c) is a *PARP-1* inhibitor (IC₅₀: 26 nM). PARP-1-IN-13 inhibits DNA single-strand breakage repair and aggravates DNA double-strand breakage. PARP-1-IN-13 promotes the apoptosis of cancer cells through the mitochondrial apoptosis pathway .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP* activity .

HY-151609

PARP7-IN-12

PARP Cancer

PARP7-IN-12 is a potent PARP7 Inhibitor with an IC₅₀ value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .
HY-163081

PARP7-IN-17

PARP Cancer

PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .
HY-162114

PARP1-IN-18

PARP Cancer

PARP1-IN-18 (compound 25) is a potent PARP1 inhibitor with an IC₅₀ value of 2.7 nM. PARP1-IN-18 has anticancer effects .

PARP7-IN-12	PARP	Cancer
PARP7-IN-12 is a potent *PARP7* Inhibitor with an IC₅₀ value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of *PARP7* with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

PARP1-IN-18	PARP	Cancer
PARP1-IN-18 (compound 25) is a potent *PARP1* inhibitor with an IC₅₀ value of 2.7 nM. PARP1-IN-18 has anticancer effects .

HY-149001

PARP1-IN-9	PARP	Cancer
PARP1-IN-9 (Compound 5c) is a PARP1 inhibitor with an IC₅₀ of 30.51 nM. PARP1-IN-9 induces cell apoptosis and shows anticancer activity. PARP1-IN-9 has higher potency than Olaparib (HY-10162) .

HY-162172

PARP7-IN-18	PARP	Cancer
Parp7-in-18 (Compund 8) is a selective *PARP7* inhibitor with an IC₅₀ of 0.11 nM. PARP7-IN-18 exhibits good anticancer activity and pharmacokinetic properties .

HY-144642

PARP-1-IN-1	PARP	Cancer
PARP-1-IN-1 is a high selective and orally active *PARP-1* inhibitor (IC₅₀=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model .

HY-147027

PARP-1-IN-2	PARP Caspase Apoptosis	Cancer
PARP-1-IN-2 (compound 11g) is a potent and BBB-penetrated *PARP1* inhibitor, with an IC₅₀ of 149 nM. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .

HY-156419

PARP7-IN-16	PARP	Cancer
PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of *PARP-1/2/7, with IC₅₀s of 0.94, 0.87 and 0.21 nM, respectively. PARP*7-IN-16 can be used for the research of breast cancer and prostate cancer .

HY-146502

PARP10/15-IN-3	PARP Apoptosis	Cancer
PARP10/15-IN-3 (Compound 8a) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.14 µM and 0.40 µM against PARP10 and PARP15, respectively. PARP10/15-IN-3 is able to enter cells and rescue cells from apoptosis .

HY-150765

PARP1-IN-12	PARP Apoptosis	Cancer
PARP1-IN-12 is a potent *PARP1* inhibitor with an IC₅₀ of 2.99 nM. PARP1-IN-12 exhibits antiproliferative activity, can induce cell apoptosis and cause cycle arrest at G2/M phase. PARP1-IN-12 also can induce DNA double strand breaks (DSBs) in BRCA-deficient cells .

HY-156298

PARP1-IN-16	PARP Apoptosis	Cancer
PARP1-IN-16 (compound 12a) is a potent *PARP1* inhibitor, with an IC₅₀ of 1.89 nM. PARP1-IN-16 can arrest the cell cycle in S phase and induce apoptosis in HCT-116 cells .

HY-146501

PARP10/15-IN-2	PARP Apoptosis	Cancer
PARP10/15-IN-2 (Compound 8h) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.15 µM and 0.37 µM against PARP10 and PARP15, respectively. PARP10/15-IN-2 is able to enter cells and rescue cells from apoptosis .

HY-160417

PARP1-IN-19

PARP Cancer

PARP1-IN-19 is a PARP1 inhibitor with antitumor effects (CN107955001A; Embodiment 3) .

PARP1-IN-19	PARP	Cancer
PARP1-IN-19 is a *PARP1* inhibitor with antitumor effects (CN107955001A; Embodiment 3) .

HY-143398

PARP10/15-IN-1	PARP	Cancer
PARP10/15-IN-1 (compound 8l) is a potent inhibitor of dual inhibitor of *PARP10* and *PARP15, with IC₅₀s of 160 nM and 370 nM, respectively. PARP*10/15-IN-1 can be used for cancer .

HY-142657

PARP1-IN-7

PARP Cancer

PARP1-IN-7 is an inhibitor of poly(ADP-ribose) polymerase-1 (PARP1) as an anticancer agent.
HY-145328

PARP-1/2-IN-1

PARP Others

PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.

PARP1-IN-7	PARP	Cancer
PARP1-IN-7 is an inhibitor of poly(ADP-ribose) polymerase-1 (PARP1) as an anticancer agent.

PARP-1/2-IN-1	PARP	Others
PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.

HY-147030

PARP1-IN-8	PARP	Cancer
PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated *PARP1* inhibitor, with an IC₅₀ of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549 .

HY-155351

PARP7-IN-15

PARP Cancer

PARP7-IN-15 (Compound 18) is a PARP7 inhibitor with IC₅₀ of 0.56 nM, that has antitumor activity .

PARP7-IN-15	PARP	Cancer
PARP7-IN-15 (Compound 18) is a PARP7 inhibitor with IC₅₀ of 0.56 nM, that has antitumor activity .

HY-162349

PARP7/HDACs-IN-1	HDAC PARP	Cancer
PARP7/HDACs-IN-1 (compound 9l) is a dual-target inhibitor targeting *PARP7/HDAC* with anti-tumor activity. PARP7/HDACs-IN-1 inhibits different subtypes of PARPs and HDACs with IC₅₀s of 83.3 nM (PARP1), 3.1 nM (PARP7), 35 nM (HDAC1), 30.3 nM (HDAC2), 35.4 nM (HDAC3), and 6.4 nM respectively. (HDAC6) . br/ .

HY-149398

PARP-1/2-IN-2	Apoptosis PARP CDK	Cancer
PARP-1/2-IN-2-IN-1 (Compound 12e) is a *PARP1/2/CDK12* inhibitor (IC₅₀: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor .

HY-149003

PARP1-IN-10	PARP Apoptosis	Cancer
PARP1-IN-10 (compound 12c) is a no-cytotoxicity and potent *PARP1* inhibitor with an IC₅₀ value of 50.62 nM in vitro. PARP1-IN-10 causes cell cycle arrest at G2/M phase and apoptosis, and enhances the cytotoxicity of temozolomide (TMZ) .

HY-139879

PARP1-IN-6

PARP Cancer

PARP1-IN-6 is a dual tubulin/PARP-1 inhibitor with IC₅₀ values of 0.94 and 0.48 μM, respectively.

PARP1-IN-6	PARP	Cancer
PARP1-IN-6 is a dual *tubulin/PARP-1* inhibitor with IC₅₀ values of 0.94 and 0.48 μM, respectively.

HY-146160

PARP-1/HDAC-IN-1	PARP HDAC	Cancer
PARP-1/HDAC-IN-1 is a *PARP-1/HDAC6* dual targeting inhibitor with IC₅₀s of 68.90 nM and 510 nM, respectively. PARP-1/HDAC-IN-1 displays remarkable anticancer, anti-migration and anti-angiogenesis activities .

HY-157212

PARP-1/Proteasome-IN-1	Apoptosis PARP Proteasome	Cancer
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. *PARP-1/Proteasome*-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis .

HY-155766

PARP1-IN-14	PARP Apoptosis	Cancer
PARP1-IN-14 (compound 19k) is a potent *PARP1* inhibitor, with an IC₅₀ of 0.6 ± 0.1 nM. PARP1-IN-14 exhibits antiproliferative effect against both MDA-MB-436 (BRCA1 ^−/−) and Capan-1 (BRCA2 ^−/−) cells with IC₅₀ values below 0.3 nM .

HY-144338

PARP1/BRD4-IN-1	Epigenetic Reader Domain PARP Apoptosis DNA/RNA Synthesis	Cancer
PARP1/BRD4-IN-1 is a potent and high selective *PARP1/BRD4* inhibitor (IC₅₀s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells .

HY-117889

PARP14 inhibitor H10	PARP Apoptosis	Cancer
PARP14 inhibitor H10, compound H 10, is a selective inhibitor against *PARP14* (IC₅₀=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell apoptosis .

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2, TNKS1* and TNKS2 inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-150613

PARP1/BRD4-IN-2	Epigenetic Reader Domain PARP Apoptosis	Cancer
PARP1/BRD4-IN-2 is a potent and selective *PARP1* and BRD4 inhibitor with IC₅₀ values of 197 nM and 238 nM, respectively. PARP1/BRD4-IN-2 inhibits DNA damage repair, arrests G0/G1 transition and induces apoptosis. PARP1/BRD4-IN-2 has anti-tumor activity in MDA-MB-468 xenograft mouse model. PARP1/BRD4-IN-2 can be used for researching triple-negative breast cancer (TNBC) .

HY-161372

PARP1/c-Met-IN-1	PARP c-Met/HGFR Apoptosis	Cancer
PARP1/c-Met-IN-1 (Compound 16) is a selective dual inhibitor for *PARP1* and c-Met, with IC₅₀s of 3.3 and 32.2 nM, respectively. PARP1/c-Met-IN-1 induces cell apoptosis and cell cycle arrest in G2/M phase in MDA-MB-231 cells. PARP1/c-Met-IN-1 exhibits antitumor activity in mice .

HY-161083

PARP/EZH2-IN-2	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-2 (compound 12e) is a dual target *PARP1* and EZH2 inhibitor, with IC₅₀ values of 6.89 and 27.34 nM, respectively. PARP/EZH2-IN-2 shows anticancer activity, with no toxicity to normal cells. PARP/EZH2-IN-2 achieves synthetic lethality indirectly by inhibiting EZH2 to increase the sensitivity to PARP1, and induces cell death by regulating excessive autophagy .

HY-133124

PARP/PI3K-IN-1	PARP PI3K Apoptosis	Cancer
PARP/PI3K-IN-1 (compound 15) is a potent *PARP/PI3K* inhibitor with pIC₅₀ values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases .

HY-12022

3-Aminobenzamide 5+ Cited Publications PARP-IN-1	PARP	Cancer
3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of PARP* with IC₅₀ of* appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

1883 Compounds compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 1883 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Cat. No.	Product Name	Target	Research Area

HY-P3993A

(Gly14)-Humanin (human) (acetate) 14-Glycine-Humanin (human) (acetate)	Apoptosis	Neurological Disease
(Gly14)-Humanin (human) (14-Glycine-Humanin (human)) acetate is an analog of Humanin in which the 14th amino acid serine was replaced with glycine (Gly). (Gly14)-Humanin (human) acetate has anti-apoptotic and neuroprotective functions .

HY-P2569

Malformin A1	Apoptosis	Cancer
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-P3993

(Gly14)-Humanin (human) 14-Glycine-Humanin (human)	Apoptosis	Neurological Disease
(Gly14)-Humanin (human) (14-Glycine-Humanin (human)) is an analog of Humanin in which the 14th amino acid serine was replaced with glycine (Gly). (Gly14)-Humanin (human) has anti-apoptotic and neuroprotective functions .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6818

5,7,4'-Trimethoxyflavone	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Kaempferia parviflora Wall. ex Baker Plants Disease Research Fields Cancer Zingiberaceae	Apoptosis Caspase PARP Endogenous Metabolite CFTR
5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC₅₀ is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase *(PARP)* protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .

HY-113432

Nudifloramide 2PY	Alkaloids Structural Classification Classification of Application Fields Other disease Source classification Disease markers Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-N7569

Demethoxyfumitremorgin C	Structural Classification Alkaloids Microorganisms Source classification Marine natural products Other marine organisms Indole Alkaloids	Apoptosis Caspase PPAR
Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to **PARP/ cleavage .**

HY-P2569

Malformin A1	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Apoptosis
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-N10481

Aviculin	Classification of Application Fields Polygonum aviculare L. Polygonaceae Source classification Lignans Phenylpropanoids Plants Disease Research Fields Cancer	Apoptosis Caspase PARP Bcl-2 Family
Aviculin, a lignan glycoside, is a potent anticancer agent. Aviculin reduces metabolic activity on MCF-7 cells below 50%, with an IC₅₀ of 75.47 μM. Aviculin induces breast cancer cell apoptosis through the intrinsic apoptosis pathway. Aviculin increases expression of initiator caspase-9, executioner caspase-7, and poly (ADP-ribose) polymerase (PARP). Aviculin shows an increase in the Bax/Bcl-2 ratio .

HY-N1094

Verminoside	other families Iridoids Classification of Application Fields Anti-aging Terpenoids Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	PARP MDM-2/p53
Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of *PARP-1* and p53 proteins .

HY-W748509

Pipernonaline	Piper longum Linn. Structural Classification Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants	Caspase Apoptosis
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

HY-130476

Satratoxin G	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification	Caspase Apoptosis
Satratoxin G is a large cyclic mucor toxin. Satratoxin G induces apoptosis by activation of caspase .

HY-N1988

Cucurbitacin IIa Hemslecin A	Triterpenes Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl. Disease Research Fields Cancer	Survivin Apoptosis
Cucurbitacin IIa is a triterpene isolated from Hemsleya amalils Diels, induces apoptosis of cancer cells, reduces expression of survivin, reduces phospho-Histone H3 and increases cleaved PARP in cancer cells .

HY-122935

Nigranoic acid	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Plants Schisandraceae Disease Research Fields Schisandra chinensis (Turcz.) Baill.	HIV Reverse Transcriptase
Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model .

HY-N6861

Lucidenic acid B	Triterpenes Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Terpenoids Source classification Polyporaceae Plants Endogenous metabolite Disease Research Fields Cancer	Apoptosis
Lucidenic acid B is a natural compound isolated from Ganoderma lucidum, induces apoptosis of cancer cells, and causes the activation of caspase-9 and caspase-3, and cleavage of PARP. Lucidenic acid B does not affect the cell cycle profile, or the number of necrotic cells .

HY-N3584

Paris saponin VII 1 Publications Verification Chonglou Saponin VII	Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Disease Research Fields Steroids Cancer	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of *Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt*. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

HY-N3825

ent-Kaurane-3α,16β,17-triol	Structural Classification Terpenoids Source classification Euphorbia stracheyi Boiss. Diterpenoids Euphorbiaceae Plants	Apoptosis
ent-Kaurane-3α,16β,17-triol (Compound 3) is an anticancer agent. ent-Kaurane-3α,16β,17-triol induces apoptosis in HCT116 cells .

HY-Z0283

Benzamide Benzenecarboxamide; Phenylamide	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-N0674A

Dehydrocorydaline chloride Maximum Cited Publications 22 Publications Verification 13-Methylpalmatine chloride	Infection Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline chloride elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities . Dehydrocorydaline chloride shows strong anti-malarial effects (IC₅₀ =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N0674

Dehydrocorydaline Maximum Cited Publications 22 Publications Verification 13-Methylpalmatine	Infection Alkaloids Structural Classification Classification of Application Fields Corydalis yanhusuo W. T. Wang Source classification Plants Isoquinoline Alkaloids Disease Research Fields Papaveraceae	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities . Dehydrocorydaline shows strong anti-malarial effects (IC₅₀=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N0674B

Dehydrocorydaline (hydroxyl) 20+ Cited Publications 13-Methylpalmatine (hydroxyl)	Structural Classification Alkaloids Corydalis yanhusuo W. T. Wang Source classification Plants Papaveraceae	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.

HY-N4238

Dehydrocorydaline nitrate 20+ Cited Publications 13-Methylpalmatine nitrate	Infection Alkaloids other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. Dehydrocorydaline regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline nitrate elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. . Dehydrocorydaline nitrate shows strong anti-malarial effects (IC₅₀ =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N8572

3',4'-Dimethoxyflavone	Flavonoids other families Flavones Coniogramme japonica (Thunb.) Diels Plants	PARP Reactive Oxygen Species Aryl Hydrocarbon Receptor
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of *PARP* and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects .

HY-123033A

Nicotinamide riboside chloride 5+ Cited Publications	Alkaloids Structural Classification Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Pyridine Alkaloids Metabolic Disease Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside Chloride, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033

Nicotinamide riboside	Natural Products Human Gut Microbiota Metabolites Microorganisms Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033B

Nicotinamide riboside tartrate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside tartrate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033C

Nicotinamide riboside malate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside malate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

Species:	Human (8) Mouse (1)
Tag:	His (6) Tag Free (2) Strep (1) Avi (1) GST (2) Flag (1)
Source:	Sf9 insect cells (1) Sf9 insect cells (3) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source

HY-P74652

	PARP Protein, Human (sf9, His) ADPRT 1; ADPRT; PARP apoptosis; PARP; PPOL	Human	Sf9 insect cells
	The PARP1 protein is a polyADP-ribosyltransferase that crucially mediates polyADP-ribosylation (PARsylation) in DNA repair, including base excision and double-strand breaks. By interacting with factors such as HPF1 and NMNAT1, the specificity of PARP1 extends to various amino acids. PARP Protein, Human (sf9, His) is the recombinant human-derived PARP protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of PARP Protein, Human (sf9, His) is 1014 a.a., with molecular weight of 100-110 kDa.

HY-P73337

	PARP Protein, Mouse (sf9, His) ADPRT 1; ADPRT; PARP apoptosis; PARP; PPOL	Mouse	Sf9 insect cells
	PARP, a poly-ADP-ribosyltransferase, catalyzes poly-ADP-ribosylation, crucial for DNA repair. This protein irreversibly binds to DNA breaks, disrupting repair processes and triggering DNA damage-induced apoptosis. PARP Protein, Mouse (sf9, His) is the recombinant mouse-derived PARP protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of PARP Protein, Mouse (sf9, His) is 1014 a.a., with molecular weight of ~75 kDa.

HY-P75955

	PARP3 Protein, Human (sf9, His-GST) Protein mono-ADP-ribosyltransferase PARP3; ARTD3; IRT1; ADPRT-3; PARP-3	Human	Sf9 insect cells
	The PARP3 protein is a mono-ADP ribosyltransferase that responds to DNA damage, focusing on mono-ADP ribosylation of proteins such as histone H2B, XRCC5, and XRCC6. PARP3 plays a key role in the DNA repair process, participating in precise nonhomologous end joining and inhibiting G-quadruplex structure. PARP3 Protein, Human (sf9, His-GST) is the recombinant human-derived PARP3 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of PARP3 Protein, Human (sf9, His-GST) is 533 a.a., with molecular weight of ~95 kDa.

HY-P701954

	PARP6 Protein, Human PARP6; Protein mono-ADP-ribosyltransferase PARP6; ADP-ribosyltransferase diphtheria toxin-like 17; ARTD17; Poly [ADP-ribose] polymerase 6; PARP-6	Human	E. coli
	PARP6 protein, a mono-ADP-ribosyltransferase, specializes in mediating the mono-ADP-ribosylation of target proteins. PARP6 Protein, Human is the recombinant human-derived PARP6 protein, expressed by E. coli , with tag free. The total length of PARP6 Protein, Human is 227 a.a., .

HY-P701955

	PARP6 Protein, Human (FLAG, GST, Avi) PARP6; Protein mono-ADP-ribosyltransferase PARP6; ADP-ribosyltransferase diphtheria toxin-like 17; ARTD17; Poly [ADP-ribose] polymerase 6; PARP-6	Human	E. coli
	PARP6 protein, a mono-ADP-ribosyltransferase, specializes in mediating the mono-ADP-ribosylation of target proteins. PARP6 Protein, Human (FLAG, GST, Avi) is the recombinant human-derived PARP6 protein, expressed by E. coli , with C-Avi, N-Flag, N-GST labeled tag. The total length of PARP6 Protein, Human (FLAG, GST, Avi) is 227 a.a., .

HY-P701951

	PARP14 Protein, Human PARP14; Protein mono-ADP-ribosyltransferase PARP14; ADP-ribosyltransferase diphtheria toxin-like 8; ARTD8; B aggressive lymphoma protein 2; Poly [ADP-ribose] polymerase 14; PARP-14	Human	E. coli
	The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human is the recombinant human-derived PARP14 protein, expressed by E. coli , with tag free. The total length of PARP14 Protein, Human is 180 a.a., .

HY-P701952

	PARP14 Protein, Human (His, Strep) PARP14; Protein mono-ADP-ribosyltransferase PARP14; ADP-ribosyltransferase diphtheria toxin-like 8; ARTD8; B aggressive lymphoma protein 2; Poly [ADP-ribose] polymerase 14; PARP-14	Human	E. coli
	The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human (His, Strep) is the recombinant human-derived PARP14 protein, expressed by E. coli , with N-Strep, N-8*His labeled tag. The total length of PARP14 Protein, Human (His, Strep) is 180 a.a., .

HY-P701953

	PARP15 Protein, Human (His) PARP15; Protein mono-ADP-ribosyltransferase PARP15; ADP-ribosyltransferase diphtheria toxin-like 7; ARTD7; B-aggressive lymphoma protein 3; Poly [ADP-ribose] polymerase 15; PARP-15	Human	E. coli
	PARP15 protein, acting as a mono-ADP-ribosyltransferase, facilitates the mono-ADP-ribosylation of target proteins. It also functions as a transcriptional negative regulator, impacting cellular processes and gene expression. PARP15 Protein, Human (His) is the recombinant human-derived PARP15 protein, expressed by E. coli , with N-6*His labeled tag. The total length of PARP15 Protein, Human (His) is 176 a.a., .

HY-P702585

	PARP2 Protein, Human (sf9, His) Poly [ADP-ribose] polymerase 2; ADP-ribosyltransferase diphtheria toxin-like 2; DNA ADP-ribosyltransferase PARP2; NAD(+) ADP-ribosyltransferase 2; ADPRT-2; pADPRT-2; EC:2.4.2.30; ADPRT2; ADPRTL2	Human	Sf9 insect cells

Cat. No.	Product Name	Chemical Structure

HY-10162S

Olaparib-d5

Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].
HY-Z0283S

Benzamide-15N

Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-10162S1

Olaparib-d8
Olaparib-d₈ is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-10162S3

Olaparib-d4-1
Olaparib-d₄-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-113432S

Nudifloramide-d3
Nudifloramide-d₃ (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].

Cat. No.	Product Name	Application	Reactivity

HY-P80263

PARP1 Antibody PARP-1; ARTD1; ADPRT 1; PARP1	WB, ICC/IF, IHC-P, FC	Human, Mouse
PARP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 113 kDa, targeting to PARP. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

HY-P80265

PARP2 Antibody	WB, FC	Human
PARP2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 66 kDa, targeting to PARP2. It can be used for WB,FC assays with tag free, in the background of Human.

HY-P80625

*Cleaved-PARP1 Antibody* PARP1; ADPRT; PPOL; Poly [ADP-ribose] polymerase 1; PARP-1; ADP-ribosyltransferase diphtheria toxin-like 1; ARTD1; NAD(+) ADP-ribosyltransferase 1; ADPRT 1; Poly[ADP-ribose] synthase 1	WB	Human
Cleaved-PARP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 113 kDa, targeting to Cleaved-PARP1. It can be used for WB assays with tag free, in the background of Human.

HY-P80780

PARP1 Antibody (YA245) PARP1; ADPRT; PPOL; Poly [ADP-ribose] polymerase 1; PARP-1; ADP-ribosyltransferase diphtheria toxin-like 1; ARTD1; NAD(+) ADP-ribosyltransferase 1; ADPRT 1; Poly[ADP-ribose] synthase 1	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
PARP1 Antibody (YA245) is a non-conjugated and Rabbit origined monoclonal antibody about 113 kDa, targeting to PARP1. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80448

*Cleaved PARP* Antibody**	WB, ICC, IP, FC	Human
Cleaved PARP Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 89 kDa, targeting to Cleaved PARP. It can be used for WB,ICC,IP,FC assays with tag free, in the background of Human.

Cat. No.	Product Name		Classification

HY-150221

DB008		Alkynes
DB008 is potent and selective *PARP16* inhibitor with an IC₅₀ value of 0.27 μM, containing an acrylamide electrophilic reagent. DB008 is membrane-permeable and marks PARP16 selectively . DB008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130652

Pomalidomide 4'-PEG3-azide		Azide
Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3 is a highly efficient *PARP1*?degrader based on Rucaparib by using the PROTAC approach . Pomalidomide 4'-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-W021401

Amino-PEG3-C2-Azido		Azide PROTAC Synthesis
Amino-PEG3-C2-Azido is a PEG-based PROTAC linker can be used in the synthesis of the PARP1 degrader iRucaparib-TP3 (HY-130645) . Amino-PEG3-C2-Azido is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-145749

PARPYnD		Alkynes
PARPYnD is a *PARP* enzyme photoaffinity probe (AfBP) based on the triple *PARP1/2/6* inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

HY-130654

(S,R,S)-AHPC-C2-PEG4-N3 VH032-C2-PEG4-N3		Azide
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC₅₀) of 82 nM . (S,R,S)-AHPC-C2-PEG4-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry